Multifactorial diagnostic NIR imaging of CCK2R expressing tumors

Biomaterials

Volumn 34, Issue 21, 2013, Pages 5172-5180

  Kossatz, Susanne ^a   Béhé, Martin ^b   Mansi, Rosalba ^c   Saur, Dieter ^d   Czerney, Peter ^e   Kaiser, Werner A ^a   Hilger, Ingrid ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b ETH Zurich   (Switzerland)

^c UNIVERSITY OF FREIBURG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e Dyomics GmbH   (Germany)

Author keywords

CCK2 receptor; Invivo optical imaging; Minigastrin; Multifactorial imaging; Optical peptide probes; Tumor metabolism

Indexed keywords

CCK2-RECEPTOR; ENDOSCOPIC APPLICATIONS; HISTOLOGICAL EXAMINATION; INTRAVENOUS INJECTIONS; MINIGASTRIN; MULTIFACTORIAL APPROACH; OPTICAL IMAGING; TUMOR METABOLISMS;

BIOLOGICAL MATERIALS; ENDOSCOPY; FLUORESCENCE; METABOLISM; OPTICAL IMAGE STORAGE; PEPTIDES; PHARMACOKINETICS; PHYSIOLOGY; PROBES;

TUMORS;

CHOLECYSTOKININ B RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CHEMICAL STRUCTURE; DIAGNOSTIC IMAGING; ENDOSCOPY; FLUORESCENCE IMAGING; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL; TUMOR DIAGNOSIS; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; FEMALE; GLYCOLYSIS; HUMANS; MICE; MICE, NUDE; MOLECULAR PROBES; NEOPLASMS; RECEPTOR, CHOLECYSTOKININ B; SPECTROSCOPY, NEAR-INFRARED; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84877021849     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.073     Document Type: Article

References (41)

1. van Dam G.M., Themelis G., Crane L.M., Harlaar N.J., Pleijhuis R.G., Kelder W., et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med 2011, 17(10):1315-1319.
2. Terwisscha van Scheltinga A.G.T., van Dam G.M., Nagengast W.B., Ntziachristos V., Hollema H., Herek J.L., et al. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. JNucl Med 2011, 52(11):1778-1785.
3. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46(4):765-781.
4. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
5. Mahmood U., Upadhyay R. Current and future imaging paradigms in colorectal cancer. Semin Colon Rectal Surg 2007, 18(2):132-138.
6. Smith A.M., Watson S.A. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. Gut 2000, 47(6):820-824.
7. Morton M., Prendergast C., Barrett T.D. Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer. Trends Pharmacol Sci 2011, 32(4):201-205.
8. Schmitz F., Otte J.M., Stechele H.U., Reimann B., Banasiewicz T., Folsch U.R., et al. CCK-B/gastrin receptors in human colorectal cancer. Eur J Clin Invest 2001, 31(9):812-820.
9. Imdahl A., Mantamadiotis T., Eggstein S., Farthmann E.H., Baldwin G.S. Expression of gastrin, gastrin/CCK-B and gastrin/CCK-C receptors in human colorectal carcinomas. JCancer Res Clin Oncol 1995, 121(11):661-666.
10. Reubi J.C., Schär J.-C., Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997, 57:1377-1386.
11. Yu H.G., Tong S.L., Ding Y.M., Ding J., Fang X.M., Zhang X.F., et al. Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase. Int J Cancer 2006, 119(12):2724-2732.
12. Huang H., Ansorge N., Schrader H., Banasch M., Yu H.G., Schmidt W.E., et al. The CCK-2/gastrin splice variant receptor retaining intron 4 transactivates the COX-2 promoter invitro. Regul Pept 2007, 144(1-3):34-42.
13. Chao C., Han X., Ives K., Park J., Kolokoltsov A.A., Davey R.A., et al. CCK(2) receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells. Int J Cancer 2010, 15(4):864-875.
14. Jin G., Ramanathan V., Quante M., Baik G.H., Yang X., Wang S.S.W., et al. Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice. JClin Invest 2009, 119(9):2691-2701.
15. Behr T.M., Jenner N., Béhé M., Angerstein C., Gratz S., Raue F., et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. JNucl Med 1999, 40:1029-1044.
16. Laverman P., Joosten L., Eek A., Roosenburg S., Kolenc-Peitl P., Maina T., et al. Comparative biodistribution of 12(111)In-labelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging 2011, 38(8):1410-1416.
17. Aloj L., Aurilio M., Rinaldi V., D'ambrosio L., Tesauro D., Kolenc-Peitl P., et al. Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging 2011, 38(8):1417-1425.
18. Laabs E., Béhé M., Kossatz S., Frank W., Kaiser W.A., Hilger I. Optical imaging of CCK[U+2082]/gastrin receptor-positive tumors with a minigastrin near-infrared probe. Invest Radiol 2011, 46(3):196-201.
19. Mahmood U. Optical molecular imaging approaches in colorectal cancer. Gastroenterology 2010, 138(2):419-422.
20. Gillies R.J., Robey I., Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. JNucl Med 2008, 49(Suppl. 2):24S-42S.
21. Moreno-Sánchez R., Rodríguez-Enríquez S., Marín-Hernández A., Saavedra E. Energy metabolism in tumor cells. FEBS J 2007, 274(6):1393-1418.
22. Kovar J.L., Volcheck W., Sevick-Muraca E., Simpson M.A., Olive D.M. Characterization and performance of a near-infrared 2-deoxyglucose optical imaging agent for mouse cancer models. Anal Biochem 2009, 384(2):254-262.
23. Keereweer S., Kerrebijn J.D.F., Mol I.M., Mieog J.S.D., Driel Van P.B.A.A., Jong De R.J.B., et al. Optical imaging of oral squamous cell carcinoma and cervical lymph node metastasis. Head Neck 2012, 34(7):1002-1008.
24. Tseng J.-C., Wang Y., Banerjee P., Kung A.L. Incongruity of imaging using fluorescent 2-DG conjugates compared to (18)F-FDG in preclinical cancer models. Mol Imaging Biol 2012, 14(5):553-560.
25. Aloj L., Caracó C., Panico M., Zannetti A., Vecchio Del S., Tesauro D., et al. Invitro and invivo evaluation of 111 In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. JNucl Med 2004, 45(3):485-494.
26. Simms D., Cizdziel P.E., Chomczynski P. Trizol: a new reagent for optimal single-step isolation of RNA. Focus 1993, 15(4):99-102.
27. Kolenc-Peitl P., Mansi R., Tamma M., Gmeiner-Stopar T., Sollner-Dolenc M., Waser B., et al. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. JMed Chem 2011, 54(8):2602-2609.
28. Limame R., Wouters A., Pauwels B., Fransen E., Peeters M., Lardon F., et al. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PloS One 2012, 7(10):e46536.
29. Vermeulen P.B., Gasparini G., Fox S.B., Colpaert C., Marson L.P., Gion M., et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002, 38(12):1564-1579.
30. Dhakal H.P., Naume B., Synnestvedt M., Borgen E., Kaaresen R., Schlichting E., et al. Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination. Clin Cancer Res 2008, 14(8):2341-2350.
31. Fox S.B., Gasparini G., Harris A.L. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001, 2(5):278-289.
32. Hamann F.M., Brehm R., Pauli J., Grabolle M., Frank W., Kaiser W.A., et al. Controlled modulation of serum protein binding and biodistribution of asymmetric cyanine dyes by variation of the number of sulfonate groups. Mol Imaging 2011, 10(4):258-269.
33. Béhé M., Kluge G., Becker W., Gotthardt M., Behr T.M. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. JNucl Med 2005, 46(6):1012-1015.
34. Upp J.R., Singh P., Townsend C.M., Thompson J.C. Clinical significance of gastrin receptors in human colon cancers. Cancer Res 1989, 49:488-492.
35. Rehfeld J.F. Gastrin and colorectal cancer: a never-ending dispute?. Gastroenterology 1995, 108(4):1307-1310.
36. Smith A.M., Watson S.A. Review article: gastrin and colorectal cancer. Aliment Pharmacol Ther 2000, 14(10):1231-1247.
37. Sheth R.A., Mahmood U. Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol 2010, 299(4):G807-G820.
38. Frangioni J. Invivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003, 7(5):626-634.
39. Becker A., Riefke B., Ebert B., Sukowski U., Rinneberg H., Semmler W., et al. Macromolecular contrast agents for optical imaging of tumors: comparison of indotricarbocyanine-labeled human serum albumin and transferrin. Photochem Photobiol 2000, 72(2):234-241.
40. Goldshaid L., Rubinstein E., Brandis A., Segal D., Leshem N., Brenner O., et al. Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors. Breast Cancer Res 2010, 12(3):R29.
41. Gillies R.J., Anderson A.R., Gatenby R.A., Morse D.L. The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin Radiol 2010, 65(7):517-521.